BLD 3051
Alternative Names: BLD-3051Latest Information Update: 31 Aug 2022
At a glance
- Originator Blade Therapeutics
- Class Antifibrotics; Hepatoprotectants
- Mechanism of Action Calpain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatic fibrosis; Pulmonary fibrosis
Most Recent Events
-
22 Jun 2022
Pharmacodynamics data from a preclinical trial in Hepatic fibrosis presented at the International Liver Congress 2022
(ILC-2022) - 23 Sep 2021 Preclinical trials in Hepatic fibrosis in USA (unspecified route) before September 2021 (Blade Therapeutics pipeline, September 2021)
- 23 Sep 2021 Preclinical trials in Pulmonary fibrosis in USA (unspecified route) before September 2021 (Blade Therapeutics pipeline, September 2021)